<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Article Tag Suite 1.1//EN"
  "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink"
         xmlns:mml="http://www.w3.org/1998/Math/MathML"
         article-type="research-article"
         xml:lang="en">
  <front>
    <journal-meta>
      <journal-title-group>
        <journal-title>American Journal of Pharmacy and Health Research</journal-title>
        <abbrev-journal-title abbrev-type="publisher">AJPHR</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="epub">2321-3647</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.46624/ajphr.2019.v7.i8.006</article-id>
      <article-id pub-id-type="publisher-id">AJPHR708006</article-id>
      <title-group>
        <article-title>Formulation and Evaluation of Antihypertensive Bilayer Tablet</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Deokate</surname>
            <given-names>Ganesh</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>MT</surname>
            <given-names>Deshmukh</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>RV</surname>
            <given-names>Shete</given-names>
          </name>
        </contrib>
      </contrib-group>
      <pub-date pub-type="epub" iso-8601-date="2019-08-01">
        <month>08</month>
        <day>01</day>
        <year>2019</year>
      </pub-date>
      <volume>7</volume>
      <issue>8</issue>
      <abstract>
        <p>ABSTRACTThe present research work was carried out to Formulate and evaluation of Bilayer tablet dosage form for the treatment of Hypertensions. The objective of this study to compare the specific characteristics of Olmesartan midoxomil [Angiotensin II receptor antagonist] and Hydrochlorothiazide [Thiazide Diuretics] in order to design stable formulation. It can be concluded that Olmesartan Midoxomil [Angiotensin II receptor antagonist] and Hydrochlorothiazide [Thiazide Diuretics] were successfully formulated in combination as a Bilayer tablet form with Crosscarmellose sodium, Lactose monohydrate and microcrystalline cellulose PH101 for immediate release of both drugs. Both drugs were found to be stable in Bilayer tablet formulation and were found to be stable up to 6 months. This bilayer tablet dosage form increases the stability which may reduce loss and cost of formulation. It improves the benefits of producer, retailer and patients Keywords: Thiazide Diuretics, Bilayer tablet</p>
      </abstract>
      <kwd-group kwd-group-type="author">
        <kwd>Thiazide Diuretics</kwd>
        <kwd>Bilayer tablet</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <!-- Full article body not available in metadata-only JATS export. See PDF/HTML galley. -->
  </body>
  <back/>
</article>
